Thera-SAbDab

INEBILIZUMAB

>   Structural Summary
TherapeuticInebilizumab
TargetCD19
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS
Light ChainEIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedCellective Therapeutics, MedImmune
Conditions ApprovedNeuromyelitis optica
Conditions ActiveAutoimmune disorders, Myasthenia gravis, Renal transplant rejection
Conditions DiscontinuedB-cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Follicular lymphoma, Multiple myeloma, Multiple sclerosis, Systemic scleroderma
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy